Clinical Experience with ZD6474
Author Information
Author(s): Heymach J V
Primary Institution: Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute
Hypothesis
Does ZD6474 effectively inhibit tumor growth by targeting VEGF and EGF pathways?
Conclusion
ZD6474 has shown promising safety and tolerability in early clinical evaluations, with ongoing studies to assess its efficacy in various cancers.
Supporting Evidence
- ZD6474 is well tolerated at doses up to 300 mg.
- Preliminary data showed some patients with NSCLC had tumor responses.
- Combination therapies with ZD6474 and standard chemotherapy are being explored.
Takeaway
ZD6474 is a new medicine that helps fight cancer by blocking certain signals that tumors use to grow. Early tests show it is safe for patients.
Methodology
The study involved phase I and II clinical trials assessing safety, tolerability, and preliminary efficacy of ZD6474 in patients with advanced solid tumors.
Limitations
The studies primarily involved patients with advanced cancers, which may limit the generalizability of the findings.
Participant Demographics
Patients included those with various solid tumors, primarily colorectal cancer and non-small-cell lung cancer.
Statistical Information
P-Value
<0.2
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website